Basic research

Phenotype and function of NK cell in colorectal cancer

  • Xujiao FENG ,
  • Jianyue LIU ,
  • Yangyang QI ,
  • Jing SUN ,
  • Lei SHEN
Expand
  • 1.Shanghai Institute of Immunology; Department of Immunology and Microbiology, Shanghai Jiao Tong University College of Basic Medical Sciences, Shanghai 200025, China
    2.Department of General Surgery, Shanghai Minimally Invasive Surgery Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    3.Center for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
SHEN Lei, E-mail: lshen@shsmu.edu.cn.

Received date: 2023-12-18

  Accepted date: 2024-03-06

  Online published: 2024-06-28

Supported by

National Key Research and Development Program of China(2020YFA0509203);Shanghai Science and Technology Commission Science and Technology Innovation Program in Basic Research Area(20JC1410100)

Abstract

Objective ·To investigate the composition of immune cells in tumor microenvironment of colorectal cancer (CRC), and examine the proportion, phenotype and effector function of natural killer (NK) cells in CRC. Methods ·Fresh tumor tissues, paired normal tissues adjacent to tumor, and peripheral blood samples in the same cohort were collected from CRC patients. Tissues were digested and prepared into single cell suspension. The major immune cell lineages were detected by flow cytometry. t-Distributed stochastic neighbor embedding (t-SNE) and statistical analysis were used to analyze the composition of immune cells in tumor microenvironment of CRC. To analyze the phenotype of NK cells, the expression levels of activation markers, including CD16, CD27, CD69, human leukocyte antigen-DR (HLA-DR), and T cell immunoglobulin domain and mucin domain-3 (TIM-3), were detected by flow cytometry. NK cell subsets: CD38lowNK cells and CD38highNK cells were also examined by flow cytometry. To assess the effector function of NK cells, they were stimulated with cell stimulation cocktail and the expression levels of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were measured by flow cytometry. Results ·Twenty-five pairs of fresh tumor tissues and normal tissues adjacent to tumor, and 15 peripheral blood samples in the same cohort were collected from CRC patients. The tumor microenvironment of CRC included diverse immune cell types, including T cells, B cells, NK cells and myeloid cells. The proportions of T cells (P=0.000) and myeloid cells (P=0.026) in tumor tissues were significantly higher than those in normal tissues. By contrast, the proportion of NK cells (P=0.007) in tumor was significantly reduced. The proportion of B cells was comparable between tumor and normal tissues. Compared to normal tissues, NK cells in tumor tissues expressed significantly lower CD27 (P=0.000) and CD69 (P=0.001), while the expression levels of CD16 (P=0.008), HLA-DR (P=0.000) and TIM-3 (P=0.024) were significantly elevated. The results indicated that NK cells in CRC tumor exhibited a phenotype of late activation and exhaustion. According to the expression level of CD38, NK cells could be divided into two subsets, CD38highNK cells and CD38lowNK cells. The proportion of CD38highNK cells (P=0.003) in tumor tissues was significantly lower than that in normal tissues, while the proportion of CD38lowNK cells was unaffected. Compared to CD38lowNK cells, CD38highNK cells expressed higher CD27, meanwhile significantly less CD16, NKp46, CD57, CD94, HLA-DR and CD158a (P=0.000). These results suggested that CD38highNK cells were at early differentiation state. The secretion of cytokines IFN-γ (P=0.032), TNF-α (P=0.042), and GM-CSF (P=0.019) by tumor-infiltrated NK cells was significantly decreased compared to that in normal tissues. The results showed that the function of tumor-infiltrated NK cells was impaired. Conclusion ·Together, these data suggest that NK cell compartment is disrupted in tumor tissues of CRC, leading to the impaired anti-tumor immunity mediated by NK cells.

Cite this article

Xujiao FENG , Jianyue LIU , Yangyang QI , Jing SUN , Lei SHEN . Phenotype and function of NK cell in colorectal cancer[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024 , 44(6) : 713 -722 . DOI: 10.3969/j.issn.1674-8115.2024.06.006

References

1 SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2 SIEGEL R L, WAGLE N S, CERCEK A, et al. Colorectal cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(3):233-254.
3 XU L Y, ZHAO J H, LI Z H, et al. National and subnational incidence, mortality and associated factors of colorectal cancer in China: a systematic analysis and modelling study[J]. J Glob Health, 2023, 13: 04096.
4 LI N, LU B, LUO C Y, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America[J]. Cancer Lett, 2021, 522: 255-268.
5 HOSSAIN M S, KARUNIAWATI H, JAIROUN A A, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies[J]. Cancers, 2022, 14(7): 1732.
6 ZENG H M, RAN X H, AN L, et al. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study[J]. Lancet Public Health, 2021, 6(12): e877-e887.
7 TESTA U, PELOSI E, CASTELLI G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells[J]. Med Sci, 2018, 6(2): 31.
8 MEZHEYEUSKI A, MICKE P, MARTíN-BERNABé A, et al. The immune landscape of colorectal cancer[J]. Cancers (Basel), 2021, 13(21): 5545.
9 LIU S Z, GALAT V, GALAT Y, et al. NK cell-based cancer immunotherapy: from basic biology to clinical development[J]. J Hematol Oncol, 2021, 14(1): 7.
10 MYERS J A, MILLER J S. Exploring the NK cell platform for cancer immunotherapy[J]. Nat Rev Clin Oncol, 2021, 18(2): 85-100.
11 BRUNI D, ANGELL H K, GALON J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy[J]. Nat Rev Cancer, 2020, 20(11): 662-680.
12 TANG Y P, XIE M Z, LI K Z, et al. Prognostic value of peripheral blood natural killer cells in colorectal cancer[J]. BMC Gastroenterol, 2020, 20(1): 31.
13 MENON A G, JANSSEN-VAN RHIJN C M, MORREAU H, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis[J]. Lab Invest, 2004, 84(4): 493-501.
14 DONADON M, HUDSPETH K, CIMINO M, et al. Increased infiltration of natural killer and T cells in colorectal liver metastases improves patient overall survival[J]. J Gastrointest Surg, 2017, 21(8): 1226-1236.
15 HALAMA N, BRAUN M, KAHLERT C, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines[J]. Clin Cancer Res, 2011, 17(4): 678-689.
16 COPPOLA A, ARRIGA R, LAURO D, et al. NK cell inflammation in the clinical outcome of colorectal carcinoma[J]. Front Med (Lausanne), 2015, 2: 33.
17 SORRENTINO C, D'ANTONIO L, FIENI C, et al. Colorectal cancer-associated immune exhaustion involves T and B lymphocytes and conventional NK cells and correlates with a shorter overall survival[J]. Front Immunol, 2021, 12: 778329.
18 JOBIN G, RODRIGUEZ-SUAREZ R, BETITO K. Association between natural killer cell activity and colorectal cancer in high-risk subjects undergoing colonoscopy[J]. Gastroenterology, 2017, 153(4): 980-987.
19 GANESH K, STADLER Z K, CERCEK A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6): 361-375.
20 BAI Z Y, ZHOU Y, YE Z F, et al. Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy[J]. Front Immunol, 2021, 12: 808964.
21 DE VISSER K E, JOYCE J A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth[J]. Cancer Cell, 2023, 41(3): 374-403.
22 MASKALENKO N A, ZHIGAREV D, CAMPBELL K S. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders[J]. Nat Rev Drug Discov, 2022, 21(8): 559-577.
23 CRINIER A, NARNI-MANCINELLI E, UGOLINI S, et al. SnapShot: natural killer cells[J]. Cell, 2020, 180(6): 1280-1280.e1.
24 HASHEMI E, MALARKANNAN S. Tissue-resident NK cells: development, maturation, and clinical relevance[J]. Cancers, 2020, 12(6): 1553.
25 DOGRA P, RANCAN C, MA W J, et al. Tissue determinants of human NK cell development, function, and residence[J]. Cell, 2020, 180(4): 749-763.e13.
26 CAPUANO C, PIGHI C, BATTELLA S, et al. Harnessing CD16-mediated NK cell functions to enhance therapeutic efficacy of tumor-targeting mAbs[J]. Cancers, 2021, 13(10): 2500.
27 MEI Y, XIAO W W, HU H, et al. Single-cell analyses reveal suppressive tumor microenvironment of human colorectal cancer[J]. Clin Transl Med, 2021, 11(6): e422.
28 MERINO A M, KIM H, MILLER J S, et al. Unraveling exhaustion in adaptive and conventional NK cells[J]. J Leukoc Biol, 2020, 108(4): 1361-1368.
29 GAO L, DU X H, LI J B, et al. Evolving roles of CD38 metabolism in solid tumour microenvironment[J]. Br J Cancer, 2023, 128(4): 492-504.
30 GARS M L, SEILER C, KAY A W, et al. CD38 contributes to human natural killer cell responses through a role in immune synapse formation[Z/OL]. bioRxiv, 2018[2023-11-16]. https://www.biorxiv.org/content/10.1101/349084v2#:~:text=CD38%20localizes%20and%20accumulates%20at%20the%20immune%20synapse,critical%20 role%20in%20NK%20cell%20immune%20synapse%20formation.
31 WEISER M R. AJCC 8th edition: colorectal cancer[J]. Ann Surg Oncol, 2018, 25(6): 1454-1455.
32 DWIVEDI S, RENDóN-HUERTA E P, ORTIZ-NAVARRETE V, et al. CD38 and regulation of the immune response cells in cancer[J]. J Oncol, 2021, 2021: 6630295.
Outlines

/